The National Acquisition Center of the U.S. Department of Veterans Affairs (VA) has awarded a $32,500,000 Blanket Purchase Agreement (BPA) to Ardelyx, Inc., a pharmaceutical company, for the supply of XPHOZAH (tenapanor), a medication used to treat hyperphosphatemia in patients on dialysis. This single-award BPA, which has an ultimate completion date of April 29, 2026, allows VA medical centers nationwide to efficiently procure the XPHOZAH medication as needed through delivery orders. Ardelyx,...
The Department of Veterans Affairs awarded a multiple-award federal supply schedule contract to Amryt Pharmaceuticals Inc. with a potential value of $225,000. The schedule is for pharmaceuticals and hematology-related products under contract number 65 IB. This enables ordering through September 2028. Additionally, the Department of Veterans Affairs National Acquisition Center awarded a single-award blanket purchase agreement to Amryt Pharmaceuticals with a value of up to $1,000,000. The BPA...
The U.S. Department of Veterans Affairs (VA) has awarded a single-award Blanket Purchase Agreement (BPA) to Ferring Pharmaceuticals Inc., a for-profit manufacturer of pharmaceutical goods, under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The $5.96 million BPA, with a period of performance through March 2026, enables the VA to procure the drug Adstiladrin (nadofaragene firadenovec), a treatment for genitourinary cancers, to support the provision of healthcare services to...
The U.S. Department of Veterans Affairs (VA) has awarded a $98.2 million multiple-award indefinite-delivery vehicle (IDV) contract under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) to Ferring Pharmaceuticals Inc., a for-profit manufacturer of pharmaceutical goods. The contract, with a period of performance through December 2025, enables the VA to efficiently procure the oncology medication Adstiladrin (nadofaragene firadenovec) to support the provision of healthcare...
The U.S. Department of Veterans Affairs (VA) has awarded a multiple-award Federal Supply Schedule (FSS) contract to Albireo Pharma, Inc., a for-profit manufacturer of pharmaceuticals and drugs. The $225,000 contract, under the Pharmaceuticals and Drugs GSA Schedule, allows the VA's Veterans Integrated Service Network 12 to order various pharmaceutical products from Albireo Pharma over a 5-year period of performance from March 2022 to March 2027. Additionally, the VA National Acquisition Center...
The Department of Veterans Affairs awarded a Federal Supply Schedule contract to Vyera Pharmaceuticals, LLC to procure drugs, pharmaceuticals, and related hematology products. The potential value of this multiple award schedule is $3.5 million with an ordering period through September 2029. Additionally, the National Acquisition Center established a single award Blanket Purchase Agreement with Vyera Pharmaceuticals on behalf of the Veterans Health Administration. Valued at $450,000, this BPA...
The key products and services being delivered under this federal contract IDV award are pharmaceutical products, primarily focused on medications used to treat nontuberculous mycobacterial lung infections and other critical respiratory conditions. The prime contractor, Insmed Inc., a global biopharmaceutical company, has been awarded a Multiple Award Federal Supply Schedule (FSS) contract valued at $24,153,150.00 by the U.S. Department of Veterans Affairs (VA) National Acquisition Center,...
The U.S. Department of Veterans Affairs (VA) has awarded a Blanket Purchase Agreement (BPA) worth up to $2,500,000 to Amneal Pharmaceuticals of New York, LLC, a for-profit limited liability company that manufactures pharmaceutical products. The BPA is for the provision of the generic drug sodium oxybate, which is used to treat narcolepsy. Amneal Pharmaceuticals holds several indefinite delivery vehicle (IDV) contracts with federal agencies, including a 5-year, $1,700,000 Federal Supply...
This Federal Supply Schedule contract was awarded by the Department of Veterans Affairs (VA) to Idorsia Pharmaceuticals US Inc., a foreign-owned, for-profit manufacturer of pharmaceuticals and related products. The $300,000 contract, with a period of performance through September 2027, is for the provision of drugs, pharmaceuticals, and hematology-related products under Schedule 65 I B. Additionally, Idorsia Pharmaceuticals US Inc. holds a $3.1 million Blanket Purchase Agreement (BPA) with the...
Phathom Pharmaceuticals, Inc. has been awarded a Federal Supply Schedule (FSS) contract IDV by the Department of Veterans Affairs (VA) to provide drugs, pharmaceuticals, and hematology-related products under FSS Schedule 65 I B. The contract, awarded to the for-profit manufacturer of goods, has a ceiling value of $25,000 and a period of performance from January 2, 2024, to June 30, 2024. This is an interim agreement to enable the VA's Veterans Integrated Service Network 12 to issue task orders...